Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

7 ALLY ROBOTIC CATARACT LASER SYSTEMS (ALLY SYSTEM) PLACEMENTS IN FIRST QUARTER 2026; BACKLOG OF 11 ALLY SYSTEMS AS OF MARCH 31, 2026

LENSAR REPORTS FIRST QUARTER 2026 RESULTS AND PROVIDES BUSINESS UPDATE

ORLANDO, FLA., APRIL 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, INC. (NASDAQ: LNSR) (LENSAR OR THE COMPANY), A GLOBAL MEDICAL TECHNOLOGY COMPANY FOCUSED ON ADVANCED ROBOTIC LASER SOLUTIONS FOR THE TREATMENT OF CATARACTS, TODAY ANNOUNCED THAT THE COMPANY'S FIRST QUARTER 2026 FINANCIAL RESULTS WILL BE RELEASED BEFORE MARKET OPEN ON FRIDAY, MAY 8, 2026.

LENSAR TO REPORT FIRST QUARTER 2026 RESULTS ON MAY 8, 2026

15 ALLY ROBOTIC CATARACT LASER SYSTEMS (ALLY SYSTEMS) PLACED IN 4Q 2025; BACKLOG OF 13 ALLY SYSTEMS PENDING INSTALLATION AS OF DECEMBER 31, 2025

LENSAR REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND PROVIDES BUSINESS UPDATE

ORLANDO, FLA., MARCH 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, INC. (NASDAQ: LNSR) (LENSAR OR THE COMPANY), A GLOBAL MEDICAL TECHNOLOGY COMPANY FOCUSED ON ADVANCED ROBOTIC LASER SOLUTIONS FOR THE TREATMENT OF CATARACTS, ANNOUNCED THAT IT REACHED AN AGREEMENT WITH ALCON RESEARCH, LLC (ALCON) TO TERMINATE THE MERGER AGREEMENT BETWEEN THE PARTIES.

LENSAR ANNOUNCES TERMINATION OF MERGER AGREEMENT WITH ALCON RESEARCH, LLC

ORLANDO, FLA., FEB. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, INC. (NASDAQ: LNSR) (LENSAR OR THE COMPANY), A GLOBAL MEDICAL TECHNOLOGY COMPANY FOCUSED ON ADVANCED ROBOTIC LASER SOLUTIONS FOR THE TREATMENT OF CATARACTS, TODAY PROVIDED AN UPDATE ON THE STATUS OF ITS PENDING ACQUISITION BY ALCON RESEARCH, LLC (ALCON).

LENSAR PROVIDES UPDATE ON PENDING ACQUISITION BY ALCON

18 ALLY ROBOTIC CATARACT LASER SYSTEMS  (ALLY SYSTEMS) PLACED IN 3Q 2025; BACKLOG OF 18 ALLY SYSTEMS PENDING INSTALLATION AS OF SEPTEMBER 30, 2025 ALLY INSTALLED BASE GREW 77% AND TOTAL LASER INSTALLED BASE GREW 20% OVER 3Q 2024 ORLANDO, FLA., NOV. 06, 2025 (GLOBE NEWSWIRE) -- LENSAR, INC. (NASDAQ: LNSR) (LENSAR OR THE COMPANY), A GLOBAL MEDICAL TECHNOLOGY COMPANY FOCUSED ON ADVANCED ROBOTIC LASER SOLUTIONS FOR THE TREATMENT OF CATARACTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025 AND PROVIDED AN UPDATE ON KEY OPERATIONAL INITIATIVES.

LENSAR REPORTS THIRD QUARTER 2025 RESULTS AND PROVIDES BUSINESS UPDATE

ORLANDO, FLA., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, INC.(NASDAQ: LNSR) (LENSAR OR THE COMPANY) TODAY ANNOUNCED THAT A MAJORITY OF THE INDEPENDENT MEMBERS OF LENSAR'S BOARD OF DIRECTORS GRANTED THREE NEWLY-HIRED NON-EXECUTIVE EMPLOYEES AN AGGREGATE OF 660 RESTRICTED STOCK UNITS (RSUS).

LENSAR REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

18 ALLY ROBOTIC CATARACT LASER SYSTEMS (ALLY SYSTEMS) PLACED IN 2Q 2025 WITH AN ADDITIONAL BACKLOG OF 18 ALLY SYSTEMS PENDING INSTALLATION AS OF JUNE 30, 2025

LENSAR REPORTS SECOND QUARTER 2025 RESULTS AND PROVIDES BUSINESS UPDATE

ORLANDO, FLA., JULY 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, INC.(NASDAQ: LNSR) (LENSAR OR THE COMPANY) TODAY ANNOUNCED THAT A MAJORITY OF THE INDEPENDENT MEMBERS OF LENSAR'S BOARD OF DIRECTORS GRANTED THREE NEWLY-HIRED NON-EXECUTIVE EMPLOYEES AN AGGREGATE OF 660 RESTRICTED STOCK UNITS (RSUS). THE RSUS WERE GRANTED AS OFJULY 1, 2025, AS INDUCEMENT FOR EACH SUCH EMPLOYEE COMMENCING EMPLOYMENT WITH THE COMPANY. THE RSUS WERE GRANTED IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF LENSAR, INC. (NASDAQCM: LNSR) TO ALCON INC. (NYSE: ALC). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF LENSAR WILL RECEIVE $14.00 IN CASH, WITH AN ADDITIONAL NON-TRADEABLE CONTINGENT VALUE RIGHT OFFERING UP TO $2.75 PER SHARE IN CASH CONDITIONED ON ACHIEVEMENT OF A MILESTONE, FOR EACH.

LENSAR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF LENSAR, INC. - LNSR

LENSAR, Inc.

LNSR

Price

Financial Reports

No items found.

Press Releases

LENSAR, Inc.

LNSR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LNSR